Science 37 Holdings, Inc. (Nasdaq: SNCE), the clinical research
industry-leading Metasite™, today announced that it has been
honored with the prestigious Frost & Sullivan Market Leadership
Award in the global decentralized clinical trials industry. This
acknowledgment highlights Science 37's accomplishments, and
solidifies its role as an industry leader, as it continues to
transform clinical trial conduct through the Metasite.
Frost & Sullivan's Best Practices Market Leadership Award is
bestowed upon companies that exhibit outstanding performance and
visionary approaches in their respective industries. The receipt of
this prestigious award highlights Science 37’s dedication to
accelerating clinical research by enabling universal trial access
for patients.
"We are proud to receive the Frost & Sullivan Market
Leadership Award," said David Coman, Chief Executive Officer at
Science 37. "This award highlights our continued leadership in
product quality, customer satisfaction, and implementation
excellence, as we continue to deliver new approaches to remote
clinical research.”
“Science 37 is committed to accelerating clinical research by
enabling access to patients anywhere,” said Manuel Albornoz, Best
Practices Research Analyst of Frost & Sullivan. “Science 37
ensures compliance with industry standards and regulatory
requirements through robust security and privacy measures and
adherence to the standards set by Good Clinical Practice (GCP)
regulations. The Metasite’s processes are user-friendly and
standardized, resulting in greater consistency, compliance, and
data accuracy.”
Science 37's unique approach is a virtual site, or Metasite,
which enables patients to participate in clinical trials from the
comfort of their homes. With investigator oversight, the Metasite
removes boundaries and enhances the participant experience with
flexible telemedicine visits, remote data capture, and convenient
scheduling times. Powered by a proprietary platform enabling
eConsent, ePRO, telemedicine, scheduling, and wearable/device
integration, the Metasite drives unified study orchestration,
greater compliance, and high-quality data—reaching patients
wherever they are. To learn more about Science 37’s Market
Leadership Award, visit www.science37.com/market-leader-award.
About Science 37Science 37 Holdings, Inc.’s (Nasdaq: SNCE)
mission is to accelerate clinical research by enabling universal
trial access for patients. Through our Metasite™ we reach an
expanded population beyond the traditional site, delivering on our
goal of clinical research that works for everyone—with greater
patient diversity. Patients gain the flexibility to participate
from the comfort of their own homes, at their local community
provider, or at a traditional site when needed. Our Metasite is
powered by a proprietary technology platform with in-house medical
and operational experts that drive uniform study orchestration,
enabling greater compliance and high-quality data. To learn more,
visit www.science37.com, or email science37@science37.com.
About Frost &
Sullivan For
six decades, Frost & Sullivan has been world-renowned for its
role in helping investors, corporate leaders, and governments
navigate economic changes and identify disruptive technologies,
Mega Trends, new business models, and companies to action,
resulting in a continuous flow of growth opportunities to drive
future success.
Cautionary Note Regarding Forward-Looking
Statements This press release contains certain
forward-looking statements within the meaning of the federal
securities laws, including statements regarding the products
offered by Science 37 and the markets in which it operates, and
Science 37’s anticipated growth and profitability. These
forward-looking statements generally are identified by the words
“believe,” “can,” “could”, “seek”, “project,” “expect,”
“anticipate,” “estimate,” “intend,” “strategy,” “future,”
“opportunity,” “plan,” “may,” “might”, “should,” “will,” “would,”
“will be,” “will continue,” “will likely result” and similar
expressions. Forward-looking statements are predictions,
projections and other statements about future events that are based
on current expectations and assumptions and, as a result, are
subject to risks and uncertainties. Many factors could cause actual
future events to differ materially from the forward-looking
statements in this press release, including but not limited to: (i)
the ability to maintain the listing of Science 37’s securities on
The Nasdaq Stock Market LLC, (ii) volatility in the price of
Science 37’s securities due to a variety of factors, including
changes in the competitive and highly regulated industries in which
Science 37 operates, variations in performance across competitors,
changes in laws and regulations affecting Science 37’s business,
changes in its capital structure, and general economic and
financial market conditions, including fluctuations in currency
exchange rates, economic instability, and inflationary conditions
(iii) the ability to implement business plans, forecasts, and other
expectations, and to identify and realize additional opportunities,
(iv) the risk that Science 37 may never achieve or sustain
profitability, (v) the risk that Science 37 will need to raise
additional capital to execute its business plan, which may not be
available on acceptable terms or at all, (vi) failure to realize
anticipated cost savings, and (vii) risks related to general
economic and financial market conditions. The foregoing list of
factors is not exhaustive. You should carefully consider the
foregoing factors and the other risks and uncertainties described
in the “Risk Factors” section of Science 37’s Annual Report on Form
10-K for the fiscal year ended December 31, 2022 filed with the
U.S. Securities and Exchange Commission (the “SEC”) on March 6,
2023 and in the other documents filed by Science 37 from time to
time with the SEC. These filings identify and address other
important risks and uncertainties that could cause actual events
and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Science 37
assumes no obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise, except as required by law. Science 37
does not give any assurance that Science 37 will achieve its
expectations.
MEDIA INQUIRIES:Grazia MohrenScience 37PR@science37.com
INVESTOR RELATIONS:Steve HalperLifeSci
AdvisorsInvestors@science37.com
Grafico Azioni Science 37 (NASDAQ:SNCE)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Science 37 (NASDAQ:SNCE)
Storico
Da Set 2023 a Set 2024